Hysteromyoma neoantigen and application thereof and hysteromyoma vaccine

A technology for uterine fibroids and vaccines, which is applied in the field of biomedicine to achieve the effect of preventing occurrence and recurrence, preventing recurrence and having good targeting.

Active Publication Date: 2020-06-19
江苏兰恩生物治疗技术研究院有限公司
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, tumor neoantigen research is focused on malignant tumors, and the expression of tumor neoantigens in benign tumors or precancerous lesions is rarely involved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hysteromyoma neoantigen and application thereof and hysteromyoma vaccine
  • Hysteromyoma neoantigen and application thereof and hysteromyoma vaccine
  • Hysteromyoma neoantigen and application thereof and hysteromyoma vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Neoantigen Binding Ability to Corresponding MHC

[0032] The affinity analysis software NetMHC software was used to analyze the binding ability of neoantigens shown in SEQ ID NO: 1 to 9 and their corresponding wild-type polypeptides to the corresponding major histocompatibility molecules (MHC), and the results are shown in Table 1 . The ability of a neoantigen to bind to the corresponding MHC is expressed by the minimum concentration of antigen polypeptide required to achieve stable MHC-antigen polypeptide binding. The lower the concentration (affinity value), the more stable the binding of the neoantigen to the MHC molecule, the stronger its antigenicity, and the better it can stimulate the proliferation of specific T cells.

[0033] Table 1 The binding ability of neoantigens and their corresponding wild-type polypeptides to corresponding MHC

[0034]

[0035]

[0036] It can be known from the results in Table 1 that the binding abilities of the neoan...

Embodiment 2

[0037] Synthesis of embodiment 2 neoantigen

[0038] The amino acid sequences of the nine neoantigens are shown in SEQ ID NO: 1 to 9, and were synthesized by GenScript Biotechnology Co., Ltd., with a purity greater than 99%, HPLC grade, and RNase-free.

Embodiment 3

[0039] Example 3 Synthesis of non-methylated oligodeoxynucleotides of full-thio-modified CpG-rich sequences

[0040] Select the agonist of TLR9--the non-methylated oligodeoxynucleotide with rich CpG sequence modified by all sulfur as one of the adjuvants of uterine leiomyoma vaccine, the unmethylated oligodeoxynucleoside with rich CpG sequence The nucleotide sequence of the acid is: 5'-TCGTCG TTT TGT CGT TTT GTC GTT GGG G-3' (SEQ ID NO: 10). Entrust GenScript Biotechnology Co., Ltd. to synthesize and fully thio-modify the non-methylated oligodeoxynucleotides of the CpG-rich sequence to obtain the fully-thio-modified non-methylated oligodeoxynucleotides of the CpG-rich sequence Acid, a synthesis of 21.8mg, approximately equal to 600OD.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a hysteromyoma neoantigen which is selected from at least one of the polypeptides whose amino acid sequence is shown as any one from SEQ ID NO:1 to SEQ ID NO:9. The hysteromyoma neoantigen can be used for the preparation of drugs for preventing hysteromyoma and / or treating hysteromyoma and / or preventing the recurrence of hysteromyoma. The invention further provides a hysteromyoma vaccine which includes the hysteromyoma neoantigen and one or more pharmaceutically acceptable carriers. The hysteromyoma vaccine has good targeting, significant effects and low side effects.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to uterine fibroid neoantigen, the application of uterine fibroid neoantigen in the preparation of medicines for preventing uterine fibroids and / or treating uterine fibroids and / or preventing recurrence of uterine fibroids and a uterine fibroid Fibroid vaccine. Background technique [0002] Uterine fibroids, also known as uterine leiomyomas, are common benign tumors in gynecology. They mostly occur in women between the ages of 30 and 50, with an incidence rate as high as 20% to 40%. The main clinical symptoms are: abdominal distension and abdominal pain , Frequent urination, urgency, irregular vaginal bleeding lead to excessive menstrual bleeding, the time is too long. Abdominal distension and abdominal pain are the most serious during menstruation, accompanied by symptoms such as bleeding and loss of libido during sexual intercourse. The severity of symptoms has a certain relat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47A61K39/00A61K39/39A61P35/00
CPCA61K39/0011A61K39/39A61K2039/5154A61P35/00C07K14/4748
Inventor 陶英亮毛力真
Owner 江苏兰恩生物治疗技术研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap